DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Continuous MONItoring of Blood LActate and Glucose Levels Using a New Central Veinous Microdialysis Catheter Device

Information source: University Hospital, Caen
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Other Functional Disturbances Following Cardiac Surgery

Intervention: comparison of blood lactate and glucose levels (Device)

Phase: N/A

Status: Recruiting

Sponsored by: University Hospital, Caen

Overall contact:
FABIEN CHAILLOT, MD, Phone: +33 2 31 06 57 74

Summary

Continuous lactate and glucose blood levels

Clinical Details

Official title: Monitorage Continu du Lactate et de la glycémie Par Microdialyse : Une étude de Validation en Chirurgie Cardiaque.

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: comparison of absolute blood lactate and glucose levels with the reference method (co oxymetry) and a new method using a device providing real time measures of lactate and glycemia with a central veinous catheter microdialysis system.

Secondary outcome: comparison of variations of blood lactate and glycemia levels with the reference method (co oxymetry) and a new method using a device providing real time measures of lactate and glycemia. (EIRUS) with a central veinous catheter microdialysis system.

Detailed description: MAQUET Group offers a new device that gives real time blood lactate and glucose levels. It is a new central veinous catheter with a microdialysis system. It is planted in the superior vena cava. It has not yet been used and validated with a clinical purpose, and particularly in cardiac surgery. For now, reference method for determining blood lactate and glucose levels is co oxymetry. This new simple device could provide great fluency for determining blood lactate and glucose levels. It could allow medical teams gain time for diagnosis and treatment of both hyperlactatemia and hyperglycemia. The primary outcome of this study was to compare blood lactate and glucose absolute measures provided with the MAQUET new device (Maquet Critical Care AB, Solna, Sweden) and with co oxymetry. The secondary outcome of this study was to compare variations of these absolutes measures.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Men or women more than 18 years old.

- Cardiac surgery.

- Central veinous catheter in superior vena cava.

Exclusion Criteria:

- Men or women less than 18 years old.

- Pregnant women.

- Central veinous catheter not in superior vena cava.

Locations and Contacts

FABIEN CHAILLOT, MD, Phone: +33 2 31 06 57 74

CHU de Caen, Caen, Basse Normandie 14000, France; Recruiting
MARC-OLIVIER FISCHER, MD
Additional Information

Starting date: November 2014
Last updated: December 7, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017